4032276 Search Results


western blotting reagent ecl prime  (Cytiva Europe)
97
Cytiva Europe western blotting reagent ecl prime
Western Blotting Reagent Ecl Prime, supplied by Cytiva Europe, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4032276/ECL+Prime+Western+Blotting+Detection+Reagent/pmc04032276-40-5-10
Average 97 stars, based on 1 article reviews
western blotting reagent ecl prime - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
revertra ace qpcr rt kit  (Toyobo)
99
Toyobo revertra ace qpcr rt kit
Revertra Ace Qpcr Rt Kit, supplied by Toyobo, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4032276/ReverTra+Ace+qPCR+RT+Kit/custom%40fsq-101%4024859235
Average 99 stars, based on 1 article reviews
revertra ace qpcr rt kit - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
gene exp gapdh mm99999915 g1  (Thermo Fisher)
99
Thermo Fisher gene exp gapdh mm99999915 g1
Gene Exp Gapdh Mm99999915 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4032276/Gene+Exp%2E+Gapdh%2C+Mm99999915_g1/pmc04032276-44-21-16
Average 99 stars, based on 1 article reviews
gene exp gapdh mm99999915 g1 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
p38 mapk  (Cell Signaling Technology Inc)
99
Cell Signaling Technology Inc p38 mapk
Neuro2a cells were treated with AMPK inhibitor compound C (10 µM) for 1 h, followed by bupivacaine (2 mM) for 9 h. (A) Expression of phospho-AMPKα (P-AMPKα), AMPK, <t>phospho-p38</t> (P-p38) and p38 was measured by Western blotting (n = 3 per group). The bar diagram shows the ratio of phospho-AMPKα to AMPK (B) and the ratio of P-p38 to p38 (C). * P <0.05, ** P <0.01 and *** P <0.001 vs. control (not treated with bupivacaine), # P <0.05, ## P <0.01 and ### P <0.001 vs. absence of compound C. All post hoc comparisons were performed by Tukey's test with repeated measures two-way ANOVA including compound C group and time period as factors and the interaction term between the two factors.
P38 Mapk, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4032276/p38+MAPK+Antibody/pmc04032276-39-34-41
Average 99 stars, based on 1 article reviews
p38 mapk - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
gene exp actb mm00607939 s1  (Thermo Fisher)
99
Thermo Fisher gene exp actb mm00607939 s1
Neuro2a cells were treated with AMPK inhibitor compound C (10 µM) for 1 h, followed by bupivacaine (2 mM) for 9 h. (A) Expression of phospho-AMPKα (P-AMPKα), AMPK, <t>phospho-p38</t> (P-p38) and p38 was measured by Western blotting (n = 3 per group). The bar diagram shows the ratio of phospho-AMPKα to AMPK (B) and the ratio of P-p38 to p38 (C). * P <0.05, ** P <0.01 and *** P <0.001 vs. control (not treated with bupivacaine), # P <0.05, ## P <0.01 and ### P <0.001 vs. absence of compound C. All post hoc comparisons were performed by Tukey's test with repeated measures two-way ANOVA including compound C group and time period as factors and the interaction term between the two factors.
Gene Exp Actb Mm00607939 S1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/4032276/Gene+Exp%2E+Actb%2C+Mm00607939_s1/pmc04032276-44-15-16
Average 99 stars, based on 1 article reviews
gene exp actb mm00607939 s1 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

Image Search Results


Neuro2a cells were treated with AMPK inhibitor compound C (10 µM) for 1 h, followed by bupivacaine (2 mM) for 9 h. (A) Expression of phospho-AMPKα (P-AMPKα), AMPK, phospho-p38 (P-p38) and p38 was measured by Western blotting (n = 3 per group). The bar diagram shows the ratio of phospho-AMPKα to AMPK (B) and the ratio of P-p38 to p38 (C). * P <0.05, ** P <0.01 and *** P <0.001 vs. control (not treated with bupivacaine), # P <0.05, ## P <0.01 and ### P <0.001 vs. absence of compound C. All post hoc comparisons were performed by Tukey's test with repeated measures two-way ANOVA including compound C group and time period as factors and the interaction term between the two factors.

Journal: PLoS ONE

Article Title: Enhanced Expression of WD Repeat-Containing Protein 35 via CaMKK/AMPK Activation in Bupivacaine-Treated Neuro2a Cells

doi: 10.1371/journal.pone.0098185

Figure Lengend Snippet: Neuro2a cells were treated with AMPK inhibitor compound C (10 µM) for 1 h, followed by bupivacaine (2 mM) for 9 h. (A) Expression of phospho-AMPKα (P-AMPKα), AMPK, phospho-p38 (P-p38) and p38 was measured by Western blotting (n = 3 per group). The bar diagram shows the ratio of phospho-AMPKα to AMPK (B) and the ratio of P-p38 to p38 (C). * P <0.05, ** P <0.01 and *** P <0.001 vs. control (not treated with bupivacaine), # P <0.05, ## P <0.01 and ### P <0.001 vs. absence of compound C. All post hoc comparisons were performed by Tukey's test with repeated measures two-way ANOVA including compound C group and time period as factors and the interaction term between the two factors.

Article Snippet: These membranes were probed with an anti-WDR35 peptide antibody (amino acids 459-473, 1∶500), which was designed, produced, and purified by Medical & Biological Laboratories (Nagoya, Japan), or with antibodies against AMPKα, phospho-AMPKα (Thr172) (P-AMPKα), p38 MAPK, phospho-p38 (P-p38) MAPK, or β-actin (Cell Signaling Technology, Danvers, MA, USA; 1∶1000).

Techniques: Expressing, Western Blot, Control

Neuro2a cells were treated with AMPK inhibitor iodotubercidin (1 µM) for 1 h, followed by bupivacaine (2 mM) for 9 h. (A) Expression of phospho-AMPKα (P-AMPKα), AMPK, phospho-p38 (P-p38) and p38 was measured by Western blotting (n = 3 per group). The bar diagram shows the ratio of phospho-AMPKα to AMPK (B) and the ratio of P-p38 to p38 (C). * P <0.05, ** P <0.01 and *** P <0.001 vs. control (not treated with bupivacaine), # P <0.05, ## P <0.01 and ### P <0.001 vs. absence of iodotubercidin. All post hoc comparisons were performed by Tukey's test with repeated measures two-way ANOVA including iodotubercidin group and time period as factors and the interaction term between the two factors.

Journal: PLoS ONE

Article Title: Enhanced Expression of WD Repeat-Containing Protein 35 via CaMKK/AMPK Activation in Bupivacaine-Treated Neuro2a Cells

doi: 10.1371/journal.pone.0098185

Figure Lengend Snippet: Neuro2a cells were treated with AMPK inhibitor iodotubercidin (1 µM) for 1 h, followed by bupivacaine (2 mM) for 9 h. (A) Expression of phospho-AMPKα (P-AMPKα), AMPK, phospho-p38 (P-p38) and p38 was measured by Western blotting (n = 3 per group). The bar diagram shows the ratio of phospho-AMPKα to AMPK (B) and the ratio of P-p38 to p38 (C). * P <0.05, ** P <0.01 and *** P <0.001 vs. control (not treated with bupivacaine), # P <0.05, ## P <0.01 and ### P <0.001 vs. absence of iodotubercidin. All post hoc comparisons were performed by Tukey's test with repeated measures two-way ANOVA including iodotubercidin group and time period as factors and the interaction term between the two factors.

Article Snippet: These membranes were probed with an anti-WDR35 peptide antibody (amino acids 459-473, 1∶500), which was designed, produced, and purified by Medical & Biological Laboratories (Nagoya, Japan), or with antibodies against AMPKα, phospho-AMPKα (Thr172) (P-AMPKα), p38 MAPK, phospho-p38 (P-p38) MAPK, or β-actin (Cell Signaling Technology, Danvers, MA, USA; 1∶1000).

Techniques: Expressing, Western Blot, Control

Neuro2a cells were treated with CaMKK inhibitor STO-609 (50 µM) for 1 h, followed by bupivacaine (2 mM) for 9 h. (A) Expression of phospho-AMPKα (P-AMPKα), AMPK, phospho-p38 (P-p38) and p38 was measured by Western blotting (n = 3 per group). The bar diagram shows the ratio of phospho-AMPKα to AMPK (B) and the ratio of P-p38 to p38 (C). ** P <0.01 and *** P <0.001 vs. control (not treated with bupivacaine), ## P <0.01 and ### P <0.001 vs. absence of STO-609. All post hoc comparisons were performed by Tukey's test with repeated measures two-way ANOVA including STO-609 group and time period as factors and the interaction term between the two factors.

Journal: PLoS ONE

Article Title: Enhanced Expression of WD Repeat-Containing Protein 35 via CaMKK/AMPK Activation in Bupivacaine-Treated Neuro2a Cells

doi: 10.1371/journal.pone.0098185

Figure Lengend Snippet: Neuro2a cells were treated with CaMKK inhibitor STO-609 (50 µM) for 1 h, followed by bupivacaine (2 mM) for 9 h. (A) Expression of phospho-AMPKα (P-AMPKα), AMPK, phospho-p38 (P-p38) and p38 was measured by Western blotting (n = 3 per group). The bar diagram shows the ratio of phospho-AMPKα to AMPK (B) and the ratio of P-p38 to p38 (C). ** P <0.01 and *** P <0.001 vs. control (not treated with bupivacaine), ## P <0.01 and ### P <0.001 vs. absence of STO-609. All post hoc comparisons were performed by Tukey's test with repeated measures two-way ANOVA including STO-609 group and time period as factors and the interaction term between the two factors.

Article Snippet: These membranes were probed with an anti-WDR35 peptide antibody (amino acids 459-473, 1∶500), which was designed, produced, and purified by Medical & Biological Laboratories (Nagoya, Japan), or with antibodies against AMPKα, phospho-AMPKα (Thr172) (P-AMPKα), p38 MAPK, phospho-p38 (P-p38) MAPK, or β-actin (Cell Signaling Technology, Danvers, MA, USA; 1∶1000).

Techniques: Expressing, Western Blot, Control